QPS ups capacity to support large-scale Ph III trials

(Image: iStock/alphaspirit)

QPS Holdings, LLC is investing in personnel and laboratory capacity for translational medicine at its headquarters in Delaware Technology Park.

According to the contract research organization (CRO), the expansion will enable it to process high sample volumes for Phase III clinical trials.

The investment is expected to result in a laboratory staff of 88, up from 57. The number of analysis teams will also increase from seven to 11.

Additionally, the CRO has created a working group to handle the demand for neutralizing antibody assays, according to QPS.

In line with the additions, the company has also expanded its dedicated immunobioanalysis and cell culture space, as well as the protein mass spectrometry area.

The company’s laboratories and testing facilities are located its headquarters in Newark, DE; Springfield, MO; Fargo, ND; Hollywood, FL; South Miami, FL, USA; Groningen, The Netherlands; Graz, Austria; Hyderabad, India; Barcelona, Spain; and Taipei, Taiwan.

Related News

Worldwide Clinical Trials is a contract research organization (CRO) with offices in North and South America, Eastern and Western Europe, Russia, and Asia. (Image: iStock/BernardaSv)

WCT selected to conduct Ph III NurOwn Trial in ALS

Kitov CEO questioned over Ph III data concerns

Kitov CEO questioned over Ph III data concerns

Acute myeloid leukemia is the most common type of acute leukemia in adults. (Image: iStock/anyaberkut)

Theradex tapped as CRO for Ph I/II AML trial

Related Products

See more related products